sellWeak cluster of 410b5-1 plan
Carl Dambkowski sold $362k of APGE
Chief Medical Officer at Apogee Therapeutics, Inc.. 5,500 shares at an average of $65.79, traded Feb 4, 2026, filed Feb 4, 2026.
Warning score
10Value
$362k
5,500 shares
Holdings after
211,148
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +15Trade size$362k at market
- 0Share of holdings soldSold 2.5% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-26-010454, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | MOption exercise Common Stock10b5-1 | +4,125 | $22.86 | $94k | 216,648 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,481 | $64.88 | $161k | 214,167 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,420 | $65.83 | $93k | 212,747 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,299 | $66.85 | $87k | 211,448 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock10b5-1 | -100 | $67.88 | $6,788 | 211,348 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $68.94 | $14k | 211,148 | Feb 4, 2026 |
| Feb 4, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,125 | $0.00 | $0 | 135,415 | Feb 4, 2026 |
Related signals
Other insiders at Apogee Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $11M 80,000 shares | -7% | |
| 33Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $3.5M 26,400 shares | -13% | |
| 38Weak | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.7M 20,000 shares | -2% | |
| 5Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $433k 5,500 shares | -3% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.6M 20,000 shares | -2% | |
| 12Weak | Apogee Therapeutics, Inc. | Carl Dambkowski Chief Medical Officer | $463k 5,500 shares | -3% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $164k 2,000 shares | -1% | |
| 22Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $180k 2,000 shares | -1% | |
| 45Moderate | Apogee Therapeutics, Inc. | Michael Thomas Henderson Chief Executive Officer | $1.7M 20,000 shares | -2% | |
| 28Weak | Apogee Therapeutics, Inc. | Jane Henderson Chief Financial Officer | $170k 2,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.